Administration of recombinant thrombomodulin before progression of disease causing disseminated intravascular coagulation might be better compared with administration after progression of disease

Table 2 Severity of illness and treatment for disseminated intravascular coagulation

	Group S (n = 57)	Group NS (n = 44)	pvalue
rTM treatment duration, days, mean ± SD	6.1 ± 2.9	6.4 ± 8.4	0.78
Dose of rTM, U/kg/day, mean ± SD	345 ± 108	308 ± 100	0.083
Duration from onset to rTM, n (%)			0.030
0 days	23 (40)	9 (20)
1 day	19 (33)	13 (30)
2 days	15 (26)	22 (50)
APACHEII at start of rTM, mean ± SD	26 ± 6	32 ± 6	<0.001
SOFA at start of rTM, mean ± SD	9.5 ± 4.2	13.4 ± 3.6	<0.001
DIC score at start of rTM, mean ± SD	5.2 ± 1.8	5.6 ± 1.7	0.20
DIC score at end of rTM, mean ± SD	3.0 ± 2.0	4.9 ± 1.9	<0.001
Ventilation with tracheal intubation, n (%)	47 (82)	43 (98)	0.01
Duration of ventilation, days, mean ± SD	11 ± 17	23 ± 38	0.038
CRRT during rTM therapy, n	33	40	<0.001
Antithrombin-III during rTM therapy, n	36	30	0.60
Globulin during rTM therapy, n	26	21	0.83
Transfusion during rTM therapy, n	43	37	0.29
Enteral nutrition during rTM therapy, n	34	18	0.11

rTM recombinant thrombomodulin, U unit, Duration from onset to rTM duration from the onset of disease causing DIC to rTM administration, APACHEII Acute Physiology and Chronic Health Evaluation II, SOFA Sequential Organ Failure Assessment scores, at start of rTM at the start of rTM administration, at end of rTM at the end of rTM administration, DIC score score of DIC criteria of the Japanese Association for Acute Medicine, CRRT continuous renal replacement therapy.

ISSN: 2052-0492